ALK and non-small cell lung carcinoma: In ALK-rearranged NSCLC, the impact of TP53 mutation is significant: a recent real-world analysis (GuardantINFORM database) of ALK TKI outcomes found that detection of a TP53 mutation was associated with a hazard ratio of 1.53 for earlier discontinuation of first-line ALK TKI therapy [59].